Synapse - Guilherme Harada

Results (28)

Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumors

Journal Article

Nykaza, I.; Murciano-Goroff, Y. R.; Desilets, A.; Harada, G.; Postow, M. A.; Callahan, M. K.; Lee, C. H.; Rudin, C. M.; Kelsen, D. P.; Stadler, Z. K.; more...
The Oncologist (2025)

Fulltext@MSK | Save

Mucocutaneous adverse events in patients with cancer treated with the highly selective RET kinase inhibitor selpercatinib (LOXO-292)

Journal Article

Reingold, R. E.; Parisi, R.; Harada, G.; Moy, A. P.; Dranitsaris, G.; Francis, J. H.; Canestraro, J.; Lester, J. A.; Kaplanis, L. A.; Liu, D.; more...
JTO Clinical and Research Reports (2025)

Fulltext@MSK | Save

Clinical characteristics and outcomes of central nervous system tumors harboring NTRK gene fusions

Journal Article

Lamoureux, A. A.; Fisher, M. J.; Lemelle, L.; Pfaff, E.; Amir-Yazdani, P.; Kramm, C.; De Wilde, B.; Kazanowska, B.; Hutter, C.; Pfister, S. M.; more...
Clinical Cancer Research (2025)

Fulltext@MSK | Save

BRAF variants and oncogenic fusions to define sporadic MMR-deficient colorectal cancer subtypes

Meeting Abstract

Abdelfattah, S.; Harada, G.; Patel, S.; Artz, O.; Yaeger, R.; Johannet, P.; Harrold, E.; Walch, H. S.; Argiles, G.; Rousseau, B.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Basket trials: Past, present, and future

Review

Murciano-Goroff, Y. R.; Uppal, M.; Chen, M.; Harada, G.; Schram, A. M.
Annual Review of Cancer Biology (2024)

Fulltext@MSK | Save

Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents

Journal Article

Roa, P.; Foglizzo, V.; Harada, G.; Repetto, M.; Kulick, A.; de Stanchina, E.; de Marchena, M.; Auwardt, S.; Sayed Ahmed, S.; Bremer, N. V.; more...
British Journal of Cancer (2024)

Fulltext@MSK | Save

TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers

Journal Article

Thawani, R.; Repetto, M.; Keddy, C.; Nicholson, K.; Jones, K.; Nusser, K.; Beach, C. Z.; Harada, G.; Drilon, A.; Davare, M. A.
npj Precision Oncology (2024)

Fulltext@MSK | Save

Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors

Journal Article

Pecci, F.; Nakazawa, S.; Ricciuti, B.; Harada, G.; Lee, J. K.; Alessi, J. V.; Barrichello, A.; Vaz, V. R.; Lamberti, G.; Di Federico, A.; more...
Cancer Discovery (2024)

Fulltext@MSK | Save

Impact of tumor-intrinsic molecular features on survival and acquired tyrosine kinase inhibitor resistance in ALK-positive NSCLC

Journal Article

Nakazawa, M.; Harada, G.; Ghanem, P.; Bubie, A.; Kiedrowski, L. A.; Murray, J. C.; Marrone, K. A.; Scott, S. C.; Houseknecht, S.; Falcon, C. J.; more...
Cancer Research Communications (2024)

Fulltext@MSK | Save

Brief report: Tyrosine kinase inhibitors for lung cancers that inhibit MATE-1 can lead to “false” decreases in renal function

Journal Article

Chen, M. F.; Harada, G.; Liu, D.; DeMatteo, R.; Falcon, C.; Wilhelm, C.; Kris, M. G.; Drilon, A.; Gutgarts, V.
Journal of Thoracic Oncology (2024)

Fulltext@MSK | Save